Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Volume 5 | Number 12 | December 2022 Editorial Board Editor-in-Chief Sharad Singhal, Phd Amit Tiwari, PhD Beckman Research Institute, City of Hope Comprehensive Cancer University of Toledo, Toledo, Ohio, USA Center, Duarte, USA Doris Germain, PhD Deputy Editor Medicine, Hematology and Medical Oncology, Richa Sharma, PhD Icahn School of Medicine at Mount Sinai, New York, USA John Wiley & Sons, Noida, India Josh Neman, PhD Associate Editors Keck School of Medicine of USC, LA, USA B.S. Dwarakanath, PhD Sathees C. Raghavan, PhD Shanghai Proton and Heavy Ion Center, Shanghai, China Indian Institute of Science, Bangalore, India Yusuke Nakamura, MD, PhD Julie Reisz Haines, PhD Cancer Precision Medicine Center, JFCR, Tokyo, Japan University of Colorado Anschutz Medical Campus, Denver, USA Haiyan Liu, PhD Shalini Singh, PhD Yong Loo Lin School of Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA National University of Singapore, Singapore Toyomasa Katagiri, PhD Jayant Sastri Goda, MD Institute for Genome Research, The University of Advanced Centre for Treatment, Research & Education Tokushima, Tokushima, Japan in Cancer, Navi Mumbai, India Douglas Hurst, PhD Argerie Tsimicalis, PhD The University of Alabama School of Medicine, Ingram School of Nursing, McGill University, Birmingham, USA Montreal, Canada Xingcai Zhang, PhD Kevin Petrie, PhD Harvard University, Cambridge, USA Biological and Environmental Sciences, Siddharth Agrawal, MD University of Stirling, Stirling, UK King George's Medical University, Lucknow, India Samir Parekh, MD Sarah-Maria Fendt, PhD Medicine, Hematology and Medical Oncology, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium Icahn School of Medicine at Mount Sinai, New York, USA Selma Bekri, PhD Advisory Board Icahn School of Medicine at Mount Sinai, New York, USA Nina Linde, PhD Gayatri Mukherjee, PhD Translational in vivo Pharcology, School of Medical Science and Technology, Merck KGaA, Darmstadt, Germany Indian Institute of Technology, Kharagpur, India Robert Weinberg, PhD Eduardo Farias, PhD Whitehead Institute for Biomedical Research, HiberCell LLC, New York, USA Massachusetts Institute of Technology, Cambridge, USA Nagraj Huilgol, MD Kenneth Yamada, MD, PhD Nanavati Hospital, Mumbai, India National Institute of Dental and Craniofacial Research, Seema Gupta, PhD National Institutes of Health, Bethesda, Maryland, USA The Jeannie and Tony Loop lab of Immune-Oncology, Samuel Waxman, MD Georgetown University, Washington D.C., USA Icahn School of Medicine at Mount Sinai, New York, USA, Samuel Gayathri R. Devi, PhD Waxman Cancer Research Foundation, New York, USA, Shanghai Jiao Tong University, Shanghai, China Duke University School of Medicine, Durham, USA Geoffery Brown, PhD Feng Liang, MD, PhD Institute of Immunology and Immunotherapy, Massachusetts General Hospital – Harvard Medical School, University of Birmingham, Birmingham, UK Boston, USA Aims and Scope Cancer Reports (Online ISSN:2573-8348) is a peer-reviewed, international, open access journal covering basic, translational, clinical and interdisciplinary cancer research in cancer biology, diagnosis, treatment, outcome, supportive care, epidemiology and health disparities. The journal considers data-driven, scientifically valid findings including incremental findings, pilot studies, replication, and negative findings. Cancer Reports is a Wiley Open Access journal, one of a new series of peer reviewed titles publishing quality research with speed and efficiency. For more information visit the Wiley Open Access website at http://www.wileyopenaccess.com. Open Access and Copyright All articles published by Cancer Reports are fully open access: immediately freely available to read, download and share. All artic les accepted from 13 August 2020 are published under the terms of the Creative Commons Attribution License. The Creative Commons Attribution License permits use, distribution and reproduction in any medium, provided the original work is properly cited and allows the commercial use of published articles. Copyright on any research article published by Cancer Reports is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher . Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identiﬁed. Further information about open access license and copyright can be found at http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright–License.htm Disclaimer The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reﬂect those of the Publisher and Editors, neither does the publication of advertisements constitute any endor sements by the Publisher and Editors of the products advertised. Wiley Open Access articles posted to repositories or websites are without warranty from Wiley of any kind, either express or implied, including, but not limited to, warranties of merchantability, ﬁtness for a particular purpose, or non-infringement. To the fullest extent permitted by law Wiley disclaims all liability for any loss or damage arising out of, or in connection with, the use of or inability to use the content For submission instructions and more journal information visit: http://www.cnr-journal.org. December 2022 | Volume 5 | Number 12 Editorial Emerging concepts in cancer therapy: Mechanisms of resistance Seema Gupta, Vivek Verma and Bilikere S. Dwarakanath Original Articles The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis Pankaj Kumar, Satish Siripini and Amere Subbarao Sreedhar Predictive biomarkers for 5-ALA-PDT can lead to personalized treatments and overcome tumor-speciﬁc resistances Maria Mastrangelopoulou, Mantas Grigalavicius, Tine H. Raabe, Ellen Skarpen, Petras Juzenas, Qian Peng, Kristian Berg and Theodossis A. Theodossiou Radiosensitization of calreticulin-overexpressing human glioma cell line by the polyphenolic acetate 7, 8-diacetoxy-4-methylcoumarin Amit Verma, Aastha Arora, Anant N Bhatt, Mohan B Arya, Ashok K Prasad, Virinder S Parmar and Bilikere S Dwarakanath Targeting radiation-induced upstream stimulatory factor-1 by histone deacetylase inhibitors to reverse radioresistance in prostate cancer Seema Gupta and Mansoor M. Ahmed Reviews Molecular and cellular paradigms of multidrug resistance in cancer Foram U. Vaidya, Abu Suﬁyan Chhipa, Vinita Mishra, Vishal Kumar Gupta, Shiv Govind Rawat, Ajay Kumar and Chandramani Pathak Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies Francesco Pezzella and Domenico Ribatti Maternal obesity and resistance to breast cancer treatments among offspring: Link to gut dysbiosis Fabia de Oliveira Andrade, Vivek Verma and Leena Hilakivi-Clarke Commentary Role of eIF4A1 in triple-negative breast cancer stem-like cell-mediated drug resistance Dayanidhi Raman and Amit K. Tiwari
Cancer Reports – Wiley
Published: Dec 1, 2022
Access the full text.
Sign up today, get DeepDyve free for 14 days.